Scarica l'app Stockscreener
3.98
4.14%
-0.1718
Precedente Chiudi:
$4.1518
Aprire:
$4.01
Volume 24 ore:
15,824
Relative Volume:
0.01
Capitalizzazione di mercato:
$5.82M
Reddito:
-
Utile/perdita netta:
$-16.49M
Rapporto P/E:
-0.1343
EPS:
-29.6295
Flusso di cassa netto:
$-15.24M
1 W Prestazione:
-15.32%
1M Prestazione:
-23.75%
6M Prestazione:
-35.49%
1 anno Prestazione:
-60.37%
Intervallo 1D:
$3.9017
$4.20
Intervallo di 1 settimana:
$3.9017
$4.64
Portata 52W:
$1.90
$12.36
Cns Pharmaceuticals Inc Stock (CNSP) Company Profile
Nome
Cns Pharmaceuticals Inc
Settore
Industria
Telefono
1-800-946-9185
Indirizzo
2100 WEST LOOP SOUTH, HOUSTON
Compare CNSP vs VRTX, REGN, ARGX, ALNY, RVMD
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
CNSP
Cns Pharmaceuticals Inc
|
3.98 | 5.82M | 0 | -16.49M | -15.24M | -29.63 |
VRTX
Vertex Pharmaceuticals Inc
|
491.34 | 124.70B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
632.90 | 66.35B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
887.18 | 55.17B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
291.37 | 38.90B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
182.08 | 38.71B | 742.00K | -1.37B | -1.07B | -7.0731 |
Cns Pharmaceuticals Inc Stock (CNSP) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2020-12-28 | Downgrade | Ladenburg Thalmann | Buy → Neutral |
| 2020-08-24 | Iniziato | Ladenburg Thalmann | Buy |
Cns Pharmaceuticals Inc Borsa (CNSP) Ultime notizie
Enterprise value to EBITDA forward of CNS Pharmaceuticals, Inc. – NASDAQ:CNSP - TradingView
Price to book forward of CNS Pharmaceuticals, Inc. – NASDAQ:CNSP - TradingView
CNS Pharmaceuticals, Inc. Actuals & Estimates (NASDAQ:CNSP) - TradingView
BE50 Forecast — Price Target — Prediction for 2027 - TradingView
Enterprise value to revenue forward of CNS Pharmaceuticals, Inc. – NASDAQ:CNSP - TradingView
CNSP Forecast — Price Target — Prediction for 2027 - TradingView
SK Biopharm taps Insilico in $2.5B AI CNS drug discovery deal - BioWorld News
ChemDiv, Inc. Highlights Successful Deployment of Proprietary CNS Drug Discovery Platform, Advancing Neurodegenerative Programs for Polku Therapeutics and Brenig Therapeutics - PR Newswire
Why did CNSP stock surge 330% today? - MSN
CNS Pharmaceuticals Inc (CNSP) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
CNS Pharmaceuticals Inc (CNSP) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
CNS Pharmaceuticals Inc (CNSP) Valuation: PE, PB & Fair Value Analysis - TradingKey
CNS Pharmaceuticals Inc (CNSP) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
CNS Pharmaceuticals Inc (CNSP) Institutional Confidence - TradingKey
CNS Pharmaceuticals Inc (CNSP) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
CNS Pharmaceuticals Inc (CNSP) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
CNS Pharmaceuticals Inc (CNSP) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
CNS Pharmaceuticals Inc (CNSP) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
CNS Pharmaceuticals Inc (CNSP) Stock Price, Quote, News & History - Benzinga
CNSP Q1 2026 Earnings: Wider Than Expected Loss, No Revenue Reported; Stock Rises 3.6%Estimate Revision Count - newsline.com
CNS Pharmaceuticals (CNSP) Tests Key Levels After Modest GainBreadth Thrust - newsline.com
What's going on with CNS Pharmaceuticals stock on Wednesday? - MSN
Relmada Therapeutics Appoints CNS Drug Development Veteran - GlobeNewswire
CNS Pharmaceuticals Company Profile & Introduction - Moomoo
CNS Pharmaceuticals (NASDAQ: CNSP) Highlights Oversubscribed $22.5M Financing, Growth Strategy in Investor Presentation - TradingView
CNS Pharmaceuticals Inc. (CNSP) Q1 2026 Earnings: Wider-than-Expected Loss Highlights Cash Burn and Pipeline ChallengesPretax Income Report - newsline.com
CNS Pharmaceuticals Highlights Oversubscribed $22.5 Million Financing and Growth Strategy - citybuzz -
CNS Pharmaceuticals CFO, Steve O'Loughlin, Highlights Company's Recent $22.5M Financing in Virtual Investor "What This Means" Segment - ACCESS Newswire
Biotech CFO breaks down oversubscribed $22.5M raise and strategy shift - Stock Titan
NRx Pharmaceuticals Closes $22.3 Million Public Offering to Support Growth and Development of CNS Therapeutics - Quiver Quantitative
CNS Pharmaceuticals (CNSP) Shows Resilience with 2% Gain, Testing Key ResistanceSeasonality Effect - newsline.com
CNSP Q1 2026 Earnings: Wider-than-Expected Loss Pressures SharesEarnings Quality Score - newsline.com
CNS Pharmaceuticals Inc. (CNSP) Q1 2026 Earnings: Wider-Than-Expected Loss as Clinical Pipeline Advances - newsline.com
CNS Pharmaceuticals Surges 11% as Biotech Sector Shows Renewed InterestDeath Cross - The Legal Advocate
CNS Pharmaceuticals (CNSP) Faces Selling Pressure as Shares Decline Over 5%Total Put Call - The Legal Advocate
CNSP Q1 2026 Earnings: Wider-than-Expected Loss Highlights Clinical-Stage Cash BurnEarnings Cycle Outlook - newsline.com
Glioblastoma Multiforme Market Poised for Significant Growth at a CAGR of 13.2% During the Forecast Period (2026–2036), as Next-Generation Therapies Enter Late-Stage Development | DelveInsight - GlobeNewswire Inc.
[EFFECT] CNS Pharmaceuticals, Inc. SEC Filing - Stock Titan
CNS Pharmaceuticals (NASDAQ: CNSP) registers 9.79M resale shares from May private placement - Stock Titan
CNSP SEC FilingsCNS Pharmaceuticals 10-K, 10-Q, 8-K Forms - Stock Titan
CNS Pharmaceuticals CEO, Rami Levin, Participates in Virtual Investor CEO Connect Segment Highlighting Company's Recent Strategic Transformation Progress - Bluefield Daily Telegraph
Insider Buying: Faith Charles Acquires Shares of CNS Pharmaceuti - GuruFocus
CNS Pharmaceuticals director Faith L. Charles buys $34,001 in stock By Investing.com - Investing.com Canada
CNS Pharmaceuticals director Faith L. Charles buys $34,001 in stock - Investing.com
CNSP | CNS Pharmaceuticals, Inc. Common Insider Trading - Quiver Quantitative
CNS Pharmaceuticals raises $22.5M to advance new biotech therapies and strategic growth. - Pluang
[Form 4] CNS Pharmaceuticals, Inc. Insider Trading Activity - Stock Titan
Cns Pharmaceuticals Inc Azioni (CNSP) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
1.36%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):